Feb 24, 2026 10:50AM Kiniksa (KNSA) PT Raised to $53 at Wedbush

Feb 19, 2026 05:30AM Canaccord Genuity Starts Kiniksa (KNSA) at Buy

Jan 12, 2026 07:34AM Kiniksa reports 62% growth in ARCALYST revenue to $677.5 million

Jan 6, 2026 09:14AM TD Cowen on Kiniksa (KNSA): 'Arcalyst Wins The Hearts Of Physicians'

Oct 28, 2025 04:43PM Kiniksa (KNSA) PT Raised to $55 at Goldman Sachs

Oct 22, 2025 08:38AM TD Cowen on Kiniksa (KNSA): 'Impressive Commercial Execution Could Support A Beat And Raise'

Oct 17, 2025 08:00AM Kiniksa receives orphan drug designation for pericarditis treatment

Sep 29, 2025 05:32AM TD Cowen Starts Kiniksa (KNSA) at Buy

Jul 29, 2025 02:45PM Kiniksa Pharmaceuticals Ltd. (KNSA) 5K contracts of October 30 calls trade, share price up 12.5%

Jul 29, 2025 01:28PM Kiniksa (KNSA) PT Raised to $54 at Jefferies

Jul 29, 2025 08:46AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 4c ; Offers Guidance

Jun 5, 2025 07:01AM Kiniksa Pharmaceuticals (KNSA) Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Apr 29, 2025 09:48AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 EPS by 9c

Feb 25, 2025 07:29AM Kiniksa Pharmaceuticals Ltd. (KNSA) Announces Development of KPL-387

Jan 13, 2025 08:48AM Goldman Sachs Reiterates Buy Rating on Kiniksa (KNSA)

Jan 13, 2025 07:31AM Kiniksa Pharmaceuticals (KNSA) Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Oct 29, 2024 04:23PM Kiniksa (KNSA) PT Raised to $35 at Evercore ISI

Oct 29, 2024 07:35AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 19c

Sep 13, 2024 03:31AM Jefferies Starts Kiniksa (KNSA) at Buy